What The Papers Say: Atopic Dermatitis treatment placed on accelerated FDA approval track

Sanofi and Regeneron Pharmaceutics, Inc, have convinced the FDA that their atopic dermatitis (AD) treatment works well enough to undergo accelerated development and regulatory review.